Non-invasive heart monitor tested against standard method in shock patients

NCT ID NCT02728791

Completed Knowledge-focused Sponsor: University Hospital, Brest Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compared a non-invasive device (ClearSight) with a standard invasive method (transpulmonary thermodilution) for measuring heart function in 42 ICU patients with shock or low cardiac output. The goal was to see if the non-invasive device could be used routinely. Researchers looked at how well the two methods agreed on cardiac index, blood pressure, and stroke volume.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If the non-invasive device proves accurate enough, it could replace invasive monitoring in some ICU patients, reducing complications.
What could go wrong: This is a small, completed correlation study (42 patients) that only compares measurements; it does not test whether using the device improves patient outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARDIAC OUTPUT, LOW are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Cardiac Output, Low Shock

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARDIAC OUTPUT, LOW SHOCK

Contacts and locations

Locations

CHRU BREST, Hôpital de la Cavale Blanche

Brest, 29200, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.